Volume 19, Number 5—May 2013
Detecting Rickettsia parkeri Infection from Eschar Swab Specimens
The typical clinical presentation of several spotted fever group Rickettsia infections includes eschars. Clinical diagnosis of the condition is usually made by analysis of blood samples. We describe a more sensitive, noninvasive means of obtaining a sample for diagnosis by using an eschar swab specimen from patients infected with Rickettsia parkeri.
Until 2004, all confirmed cases of tick-borne spotted fever in North, Central, and South America were attributed to 1 pathogen, Rickettsia rickettsii, the cause of Rocky Mountain spotted fever. Historically, in the Western Hemisphere, tick-borne rickettsiae other than R. rickettsii were often described as nonpathogens (1).
In 2004, an otherwise healthy US serviceman living in the Tidewater region of eastern Virginia, USA, sought treatment at an acute care clinic with fever, mild headache, malaise, diffuse myalgias and arthralgias, and multiple eschars on his lower extremities. He reported frequent tick and flea exposures but could not recall a specific arthropod bite before illness. However, R. parkeri, a tick-associated Rickettsia species, was subsequently isolated from an eschar biopsy specimen, documenting the first recognized case of R. parkeri rickettsiosis (2,3). In 2006, another US serviceman visited the National Naval Medical Center with similar symptoms. He had recently returned from a vacation in the Virginia Beach area; subsequently, R. parkeri was also isolated from this patient (4). To date, >25 cases of R. parkeri infections have been diagnosed in the United States and South America (5).
R. parkeri was first isolated from Gulf Coast ticks (Amblyomma maculatum) in 1937. The organism remained relatively obscure for the next several decades. R. parkeri is a member of the spotted fever group (SFG) of rickettsiae, which are gram-negative obligate intracellular rod-shaped bacteria transmitted by an arthropod vector. A. maculatum ticks, the vectors for R. parkeri in the United States, have a distribution that extends across all states bordering the Gulf of Mexico and includes several other southern, mid-Atlantic, and central states (6). R. parkeri has been detected in or isolated from A. maculatum ticks in many of these states.
Generally, the clinical signs and symptoms of SFG rickettsioses begin 6–10 days after a person has been bitten by an infected arthropod and typically include fever, headache, myalgias, a characteristic inoculation eschar at the bite site (depending on Rickettsia species) (Figure), a macular or maculopapular rash, and regional lymphadenopathy (3). SFG rickettsioses in humans range from mild to life threatening. Rocky Mountain spotted fever is considered the most severe SFG rickettsiosis; mortality rate can be as high as 50% without adequate antimicrobial drug treatment (7). Death from the rickettsioses can generally be prevented if diagnosis is timely and proper treatment is given.
In an ongoing, prospective study of clinical rickettsial disease in the Tidewater region of Virginia and Jacksonville, Florida, one of the primary objectives is to identify the prevalence of R. parkeri infection among persons seeking care with tick bite eschars or who have received a clinical diagnosis of rickettsial illness. One patient, a 43-year-old man, visited his primary care clinic in Virginia in early June 2011 after an eschar developed on his left knee, where he had removed an embedded tick 8 days previously. Topical mupirocin was prescribed for his condition. However, later that day, he experienced a fever of 104°F (40°C), accompanied by chills, night sweats, a diffuse maculopapular rash, headache, mylagias, neck stiffness, arthralgias, and malaise. He returned to the primary care clinic 3 days after onset of the fever and was prescribed a 2-week course of doxycycline. He fully recovered after the course of doxycycline.
Whole blood specimens and a swab specimen of the unroofed eschar were collected at the time he sought treatment with the acute febrile illness before doxycycline administration. Blood was collected again 25 days later during the convalescent phase. The plasma and the buffy coat were separated from the erythrocytes after centrifugation. The eschar swab was rinsed in 300 μL of phosphate-buffered saline. DNA was extracted from the buffy coat and the swab sample rinse by using QIAamp blood mini kit (QIAGEN, Germantown, MD, USA). Three microliters of the DNA preparations were applied to the Rickettsia genus–specific quantitative real-time PCRs (qPCRs) targeting the 17-kDa antigen gene (Rick17b) (8) and gltA (9), as well as the R. parkeri species–specific qPCR (Rpark), as described (8). Positive reactions were obtained from all 3 qPCRs for the swab sample and the Rick17b assay for the buffy coat. Thus, the diagnosis of R. parkeri infection in this patient was confirmed by molecular assays. The R. rickettsia–specific qPCR (Rrick) (10) yielded negative results.
Acute-phase and convalescent-phase plasma samples were tested for SFG-specific IgG and IgM by ELISA using Rickettsia conorii whole cell antigen preparation (11). The ELISA was performed side by side in 4-fold dilutions from 1:100 to 1:6,400. The SFG group–specific IgM was not detected in both samples, and the SFG group–specific IgG was also not detected in the acute sample but was detected in the convalescent-phase sample at a titer of 400. The serologic results confirmed the patient’s infection with a SFG rickettsial agent.
A second patient, a 36-year-old man, sought treatment at a primary care clinic in Pensacola, Florida, in late August 2011, 10 days after he was bitten by a tick. He was otherwise healthy, but a painless eschar had developed on his left ankle ≈4 days after exposure to the tick. Over the next several days, a generalized vesicular rash developed on his torso and upper and lower extremities, along with fevers >101°F, chills, night sweats, a mild headache, and generalized lymphadenopathy. The patient was prescribed a 14-day course of doxycycline at his initial visit. His symptoms improved within 24 hours. Serum samples were collected at his initial clinic visit, before initiation of antimicrobial drug therapy.
He returned to the clinic and was found to be asymptomatic after 14 days of treatment. Whole blood and a swab of his healing eschar—the crust was unroofed on sampling—were taken at his return visit. DNA was extracted from acute-phase serum and the eschar swab by using the same procedure as had been used for the first patient. Positive reactions were obtained from the swab sample by Rick17b and Rpark qPCRs, and negative by Rrick assay. The acute-phase serum sample was negative by all qPCRs mentioned above. The acute-phase serum and the convalescent-phase plasma samples were tested for SFG rickettsiae–specific IgM and IgG as was performed for the first patient. The titer of IgM for both samples was 400, whereas the IgG for the acute-phase serum and the convalescent-phase plasma samples were 1,600 and 6,400, respectively. The 4-fold raise in IgG titer between acute- and convalescent-phase samples provided the evidence for a current infection.
Although R. rickettsii is reportedly the predominant pathogen causing human SFG disease in the United States, the actual prevalence of R. parkeri is unknown because most commercial serologic assays do not distinguish between SFG species. Seroprevalence studies have also demonstrated higher than expected R. rickettsii seropositivity among the general population without history of Rocky Mountain spotted fever, which suggests that they may have been infected by less pathogenic SFG rickettsiae such as R. parkeri. Recently, qPCRs have demonstrated to be effective at identifying rickettsiae specific to the species level (12). A report by Bechah et al. (12) has shown that rickettsial infection could be diagnosed from noninvasively collected cutaneous lesion swab specimens from skin eschars from guinea pigs.
Using this model and our qPCR Rick17b (8), we were able to obtain positive results not only from the buffy coat sample from the Tidewater patient but also a positive reaction from a swab specimen from the eschar of the same patient. In the second patient, we were able to obtain a positive reaction from the swab specimen from the healing eschar 14 days after antimicrobial drug treatment. This finding indicates that positive reaction results may be obtained from a healing eschar 14 days after antimicrobial drug treatment and is consistent with the recent report of diagnosis of SFG from swab specimens from patients in Algeria (13). In addition, evidence is mounting that eschars can be tested for rickettsial DNA from the point of signs and symptoms all the through the convalescent phase.
Dr Myers is a Public Health Service officer and the clinical laboratory director for the Naval Infectious Diseases Diagnostic Laboratory. His research interests include clinical diagnostic assay development, medical microbiology, and molecular diagnostics.
This work was supported by funding from Armed Forces Health Surveillance Center (C0713_12_NM) and the Infectious Diseases Clinical Research Program (IDCRP-057).
- Paddock CD. Rickettsia parkeri as a paradigm for multiple causes of tick-borne spotted fever in the Western Hemisphere. Ann N Y Acad Sci. 2005;1063:315–26.
- Paddock CD, Sumner JW, Comer JA, Zaki SR, Goldsmith CS, Goddard J, Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis. 2004;38:805–11.
- Paddock CD, Finley RW, Wright CS, Robinson HN, Schrodt BJ, Lane CC, Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted fever. Clin Infect Dis. 2008;47:1188–96.
- Whitman TJ, Richards AL, Paddock CD, Tamminga CL, Sniezek PJ, Jiang J, Rickettsia parkeri infection after tick bite, Virginia. Emerg Infect Dis. 2007;13:334–6.
- Romer Y, Seijo AC, Crudo F, Nicholson WL, Varela-Stokes A, Nash RR, Rickettsia parkeri rickettsiosis, Argentina. Emerg Infect Dis. 2011;17:1169–73.
- Goddard J, Norment BR. Notes on the geographical distribution of the Gulf Coast tick, Amblyomma maculatum [Koch] [Acari:Ixodidae]. Entomol News. 1983;94:103–4.
- Parola P, Raoult D. Tropical rickettsioses. [Review]. Clin Dermatol. 2006;24:191–200.
- Jiang J, Stromdahl EY, Richards AL. Detection of Rickettsia parkeri and Candidatus Rickettsia andeanae in Amblyomma maculatum Gulf Coast ticks collected from humans in the United States. Vector Borne Zoonotic Dis. 2012;12:175–82.
- Stenos J, Graves SR, Unsworth NB. A highly sensitive and specific real-time PCR assay for the detection of spotted fever and typhus group rickettsiae. Am J Trop Med Hyg. 2005;73:1083–5.
- Jiang J, Blair PJ, Olson JG, Stromdahl E, Richards AL. Development of a duplex quantitative real-time PCR assay for the detection of tick-borne spotted fever group rickettsiae and Rickettsia rickettsii. Int Rev Armed Forces Med Serv. 2005;78:174.
- Richards AL, Soeatmadji DW, Widodo MA, Sardjono TW, Yanuwiadi B, Hernowati TE, Seroepidemiologic evidence for murine and scrub typhus in Malang, Indonesia. Am J Trop Med Hyg. 1997;57:91–5.
- Bechah Y, Socolovschi C, Raoult D. Identification of rickettsial infections by using cutaneous swab specimens and PCR. Emerg Infect Dis. 2011;17:83–6.
- Mouffok N, Socolovschi C, Benabdellah A, Renvoise A, Parola P, Raoult D. Diagnosis of rickettsioses from eschar swab samples, Algeria. Emerg Infect Dis. 2011;17:1968–9.
- Figure. . . Acute eschar of patient who was subsequently diagnosed with Rickettsia parkeri infection in Pensacola, Florida, USA, in August 2011. This same eschar was unsheathed and swabbed after 14...
Suggested citation for this article: Myers T, Lalana T, Dent M, Jiang J, Daly PL, Maguire JD, et al. Detecting Rickettsia parkeri infection from eschar swab specimens. Emerg Infect Dis. [Internet] 2013 May [date cited]. http://dx.doi.org/10.3201/eid1905.120622
Please use the form below to submit correspondence to the authors or contact them at the following address:
Todd Myers, Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring MD 20910, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 03, 2013
- Page last updated: April 03, 2013
- Page last reviewed: April 03, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)